-

Tvardi Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, in San Francisco, CA.

Presentation Details:

Date: Tuesday, January 10, 2023
Time: 5:30 p.m. PST
Location: The Westin St. Francis – Mission Bay (32nd Floor)

About Tvardi Therapeutics

Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company’s lead product, TTI-101, is completing a first-in-man Phase 1 trial of relapsed/refractory patients with advanced solid tumors. To date, TTI-101 monotherapy has been well-tolerated and has clinical activity across a broad range of tumors including multiple durable radiographic objective responses. The company has now initiated Phase 2 clinical programs in hepatocellular carcinoma, metastatic breast cancer, and idiopathic pulmonary fibrosis. To learn more, please visit https://tvarditherapeutics.com/.

Contacts

Tvardi Investor Relations
Sara Manning
ir@tvardi.com

Industry:

Tvardi Therapeutics, Inc.

Release Versions
English
Hashtags
#IPF
#breastcancer
#hepatocellularcarcinoma

Contacts

Tvardi Investor Relations
Sara Manning
ir@tvardi.com

Social Media Profiles
Tvardi LinkedIn
Tvardi Twitter
More News From Tvardi Therapeutics, Inc.

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the company’s management will participate in a fireside chat and host investor one-on-one investor meetings at the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 in New York, NY. Details are as follows: Pi...

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the third quarter ended September 30, 2025, and provided a business update. Third Quarter 2025 and Recent Highlights: Continued to progress its Phase 2 study of TTI-101 in HCC, with topline data anticipat...

Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will present at the Jefferies Global Healthcare Conference in London, UK, on Tuesday, November 18, 2025, at 9:30 AM GMT. Management will also host investor one-on-one meetings throughout the conference. The Jeffer...
Back to Newsroom